The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease by Keane, Michael P & Strieter, Robert M
BALF = bronchoalveolar lavage fluid; CCL = CC ligand; CCR = CC receptor; CXCL = CXC ligand; IFN = interferon; IL = interleukin; IL-13R = IL-
13 receptor; IL-1ra = interleukin-1 receptor antagonist; ILD = interstitial lung disease; IPF = idiopathic pulmonary fibrosis; MCP = macrophage
chemotactic protein; MIP = macrophage inflammatory protein; MMP = matrix metalloproteinase; PDGF = platelet-derived growth factor; TGF =
transforming growth factor; TNF = tumor necrosis factor.
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Introduction
The lungs comprise a unique interface between the body
and the environment, presenting an alveolar surface area of
~75 m2 and only a minimal barrier of 4–8 µm between the
alveolar airspace and the microvasculature. While this con-
figuration is ideal for gas exchange, it also increases vulner-
ability to noxious stimuli and pathogens. Consequently, the
pulmonary tissue must be able to generate a rapid innate
host defense, characterized by acute inflammation, against
both inhaled and hematogenous challenges and to
promptly clear the offending agent while not compromising
its essential gas exchange function. This acute pulmonary
inflammatory response typically results in local increases in
vascular permeability and a predominantly early neu-
trophilic influx followed by mononuclear cell infiltration.
Once the noxious agent has been successfully contained,
inflammation should then resolve with normal repair, tissue
remodeling and a return to homeostasis. Because of its
great capacity to initiate the acute inflammation of innate
immunity, however, the lung may also be predisposed to
tissue injury through excessive reactions generated by both
local and distant mediators. In conditions such as intersti-
tial lung disease (ILD), the over-exuberant tissue inflamma-
tion may result in severe irreversible lung injury mediated
primarily by elicited and activated leukocytes. This review
will focus on the balance of pro- and anti-inflammatory
mechanisms in diffuse lung disease by describing the
various cytokines involved in this balance.
Interleukin-1 family of cytokines
The interleukin-1 (IL-1) family of cytokines consists of two
agonists, IL-1α and IL-1β, and one antagonist, IL-1 recep-
tor antagonist (IL-1ra) [1]. The IL-1 agonists are protein
isoforms encoded by two distinct genes [1]. IL-1α is pre-
dominantly membrane associated whereas IL-1β is
secreted [1]. They are both produced by a variety of cells
and both bind to the type I IL-1 receptor on target cells,
eliciting similar biological functions [1]. Binding of IL-1 to
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the type I IL-1 receptor ultimately leads to release of NF-
κB for translocation to the nucleus and subsequent trans-
activation of several genes (that is, those encoding
cyclooxygenase, adhesion molecules, cytokines, NO syn-
thase, acute phase proteins, and other cytokines and
chemokines) [2,3]. As IL-1 receptors are present on
essentially all immune and non-immune system cells, IL-1
can bind and engage and elicit responses from most cells
involved in the inflammatory response.
IL-1 also binds to an IL-1 type II or ‘decoy’ receptor that
does not signal [1]. This may be a mechanism to
sequester IL-1 and stop it interacting with the IL-1 type I
receptor [1]. The IL-1 type II receptor is cleaved by metal-
loproteases on the cell surface, which releases a soluble
form of the IL-1 type II receptor that can bind IL-1β and
inhibit IL-1 signaling.
The role of the IL-1 family of cytokines in the regulation of
fibrosis in ILD is interesting, as these cytokines may have
dual and opposing functions. Both IL-1α and IL-1β induce
the expression of pro-collagen type I and type III from
fibroblasts and type IV collagen from epithelial cells, and
stimulate the production of glycosaminoglycans and
fibronectin by fibroblasts. In addition, these cytokines can
behave as indirect mitogens for fibroblast proliferation via
the expression of platelet-derived growth factor (PDGF)
and the PDGF alpha-receptor on fibroblasts. Furthermore,
IL-1α and IL-1β can serve as proximal mediators of chronic
inflammation that also promote fibrosis by inducing fibrob-
lasts to produce a variety of cytokines, including additional
IL-1, IL-6 and both CXC and CC chemokines. In contrast,
both IL-1 agonists mediate the production of tissue colla-
genase (matrix metalloproteinase (MMP)-1), gelatinase,
prostaglandin E2 and plasminogen activator. Moreover,
both can inhibit fibroblast proliferation via the production of
prostaglandin E2. It has been demonstrated recently that
transient expression of IL-1β using an adenoviral vector can
lead to progressive fibrosis long after the IL-1β levels have
declined and the acute inflammatory response has ended
[4]. In this study, an early increase in the levels of the pro-
inflammatory cytokines IL-6 and tumor necrosis factor
(TNF) and the profibrotic cytokine PDGF, and a sustained
increase in levels of transforming growth factor (TGF)-β1
[4], suggest that IL-1β has an important role in the initial
injury that leads to a self-perpetuating fibrotic response [4].
IL-1ra is a naturally occurring inhibitor of IL-1 binding to its
receptor. Thus, a dynamic balance between IL-1 agonists
and IL-1ra influences IL-1-dependent inflammation. A
variety of immune and non-immune system cells express
IL-1ra [1], which acts as a competitive antagonist of IL-1α
and IL-1β, attenuating IL-1 activity in vitro and in vivo [1].
Intracellular isoforms of IL-1ra, released after cellular injury
or apoptosis, inhibit IL-1 signaling and may play a role in
the resolution of inflammatory responses after injury.
The exogenous administration of IL-1ra can inhibit
bleomycin-induced or silica-induced pulmonary fibrosis in
mice and infusion of IL-1ra significantly attenuated lung
fibrosis [5]. No significant change was noted in the cellu-
larity of the bronchoalveolar lavage fluid (BALF) of the IL-
1ra treated animals [5]. The specific mechanism for the
decline in collagen deposition, either decreased collagen
production, increased collagen degradation or both, was
not examined in this study. Moreover, these experiments
did not determine the amount of endogenous IL-1ra nor
whether depleting endogenous IL-1ra would affect the
bleomycin-induced or silica-induced pulmonary fibrosis.
This last issue is important since IL-1ra has been found to
be significantly elevated in the BALF and interstitium of
patients with idiopathic pulmonary fibrosis (IPF) and sar-
coidosis [6].
Studies have demonstrated that patients with either sar-
coidosis or IPF have elevated levels of IL-1ra protein in
cell-free BALF that are 10-fold higher than levels of IL-1β
[6,7]; this is inhibitory for IL-1β-dependent biology [1].
IL-1ra was significantly increased in IPF lung tissue com-
pared with normal control tissue [7]. In contrast, interstitial
levels of IL-1β were significantly depressed in IPF patients
compared with normal controls [7]. Overall, the ratios of
IL-1ra to IL-1β were 19:1 in IPF patients compared to
1.3:1 in normal controls [7]. In a parallel fashion to IL-1ra,
TGF-β levels were 10-fold higher in IPF lung than in
normal lung, whereas no change was seen in the TNF
levels [7]. These disparate findings suggest that IL-1
biology is complex in ILD and that the inhibition of IL-1β
may be important in the remodeling phase of diffuse lung
disease related to pulmonary fibrosis.
Tumor necrosis factor-α α
TNF is primarily a mononuclear phagocyte-derived
cytokine that has pleiotropic effects on the inflammatory
response. It is a homotrimer that binds to two different
cell surface receptors, p55 and p75. These belong to a
unique family of receptors, the members of which are
transmembrane proteins with an extracellular cysteine-
rich domain and a more variable intracellular domain [8].
The p55 receptor and the Fas receptor contain a 60
amino acid domain, known as the ‘death domain’, that is
essential for the transduction of apoptotic signals [8]. It
has been suggested recently that ligation of the Fas
receptor and the induction of apoptosis may have an
important role in the induction of pulmonary fibrosis [9].
Like IL-1 and lipopolysaccharide (LPS), TNF-α signaling
occurs through the activation of NF-κB, which in turn
enhances the transcription of genes that mediate innate
immune responses [10].
TNF has been found to be significantly elevated in
bleomycin-induced pulmonary fibrosis and neutralization of
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parenchyma of the lung, reduces alveolar septal thickening
and decreases the disruption of the alveolar architecture,
all accompanied by a reduction in fibrosis [11]. These
results are supported by a study in which bleomycin-
treated animals received a recombinant soluble TNF recep-
tor at the time of bleomycin instillation [12]. The inhibition
of the biological effect of TNF using this strategy resulted
in a marked reduction of early as well as established pul-
monary fibrosis at both 15 and 25 days post-bleomycin
[12]. That TNF has a role in mediating pulmonary fibrosis
has been further substantiated using a transient transfer of
the gene encoding TNF-α into a rat lung [13]. The over-
expression of TNF in this lung induced severe pulmonary
inflammation and patchy interstitial fibrosis with induction
of TGF-β and increased numbers of myofibroblasts [13].
These studies support the notion that the prolonged
expression of TNF may be important in the pathogenesis of
fibrosing alveolitis, and attenuation of this cytokine may be
useful in improving the lung function of IPF patients.
The Th1/Th2 paradigm and pulmonary fibrosis
The type 1 (Th1; including IFN-γ and IL-2) and type 2
(Th2; including IL-4, IL-5, and IL-10) cytokine patterns of
immune response in mice were originally identified using
a panel of T helper cell clones. The realization that Th1
and Th2 cytokines are expressed by a variety of cells and
that the functions of these cytokines are different sug-
gests that imbalances in the expression of Th1 and Th2
cytokines may be important in dictating different
immunopathological responses [14]. For example, Th1
cytokines appear to be involved in cell-mediated immunity
associated with autoimmune disorders and allograft
rejection, whereas Th2 cytokines are predominately
involved in mediating allergic inflammation and chronic
fibroproliferative disorders, such as asthma, atopic der-
matitis, IPF and systemic sclerosis [14]. Thus, it is more
appropriate to define certain diseases in terms of the pre-
dominant cytokine profile rather than the predominant T
helper cell subset. The strict definition of Th1 and Th2
responses may break down in a scenario where the initial
inciting agent triggers an unsuccessful Th1 type
response. The subsequent host reaction to the antigen or
the chronicity of the disorder may then induce a switch to
a response dominated by Th2 cytokines. A manifestation
of this latter response is stromal cell/fibroblast prolifera-
tion and deposition of extracellular matrix, and ultimately
fibrosis. Thus, the cytokine patterns in particular diseases
are often predictable and appropriate, whereas severe
pathological consequences may result if an inappropriate
cytokine phenotype is expressed. This latter situation may
play a role in certain chronic inflammatory diseases, such
as ILD, where unknown etiologies lead to dysregulated
repair with exaggerated chronic inflammation, fibroblast
proliferation, deposition of extracellular matrix, angiogene-
sis, and finally fibrosis that accompanies end-stage pul-
monary fibrosis.
Evidence suggests that a cytokine profile of the natural
immune/inflammatory response determines the disease
phenotype responsible for either resolution or progression
to end-stage fibrosis [15,16]. Supporting evidence is
derived from studies demonstrating that interferons (IFNs),
especially IFN-γ, have profound suppressive effects on the
production of extracellular matrix proteins, such as colla-
gen and fibronectin [15,16]. IFN-γ can inhibit both fibrob-
last and chondrocyte collagen production in vitro, as well
as decrease the expression of steady state type I and III
procollagen mRNA. IFN-γ reduces PDGF-induced lung
fibroblast growth but stimulates PDGF production by alve-
olar macrophages [17]. It also up-regulates stromelysin-1
(the major matrix-degrading metalloproteinase) gene
expression by fibroblasts [18]. IFN-γ differentially regulates
intercellular adhesion molecule-1 and vascular adhesion
molecule-1 expression on fibroblasts [19]. The administra-
tion of IFN-γ in vivo can cause a reduction of extracellular
matrix in animal models of fibrosis [16]. Furthermore, we
have recently shown that IL-12 attenuates bleomycin-
induced pulmonary fibrosis via the induction of IFN-γ [20].
Moreover, IFN-γ treatment of patients with either systemic
sclerosis or IPF for one year resulted in improved pul-
monary function [21,22]. This information supports the
concept that IFN-γ is one of the major Th1 cytokines pos-
sessing profound regulatory activity for collagen deposi-
tion during chronic inflammation.
The opposing effects of Th1 and Th2 cytokines in fibrosis
are supported by a number of recent investigations
demonstrating that IL-4 is an important mediator of fibro-
blast activation [23]. In contrast to the Th1 cytokine IFN-γ,
IL-4 is a major Th2 type cytokine that promotes the pro-
duction of fibroblast-derived extracellular matrix, including
type I and III pro-collagens and fibronectin [23]. It has
been identified as a chemotactic factor for fibroblasts and
can induce fibroblast proliferation and cytokine produc-
tion. The scale of IL-4-induced fibroblast collagen synthe-
sis is similar to that induced by equal amounts of TGF-β.
Additional studies have demonstrated that fibroblasts
possess both membrane bound and soluble forms of the
IL-4 receptor. The soluble IL-4 receptor is derived from a
truncation of the membrane form and may serve either as
an IL-4 binding protein with antagonist activity or as a
carrier of IL-4 with its biological properties intact. Interest-
ingly, pulmonary expression of IL-4 in transgenic mice
leads to little or no fibrosis, suggesting a disparity
between its effect in vitro and in vivo [24]. Similarly, IL-4
depletion studies and studies with IL-4–/– mice failed to
demonstrate an indispensable role for IL-4 in models of
Th2-mediated inflammation and fibrosis [25].
Recent work has shown that fibroblast cell lines express
IL-4Rα, IL-13Rα1 and IL-13Rα2, but not the IL-2 common
γ chain necessary for specific IL-4 signaling. This sug-
gests that many of the fibroblast activation properties of
Available online http://respiratory-research.com/content/3/1/5IL-4 are shared by IL-13. As a Th2 cytokine, IL-13 has
similar biological properties to IL-4, and has been impli-
cated in the pathogenesis of fibroproliferative disorders
[26]. IL-13 induces the expression of fibroblast-derived
type I and III pro-collagens to a similar degree as IL-4 and
TGF-β [26]. It inhibits IL-1-induced matrix metallopro-
teinase (MMP)-1 and MMP-3 production, and enhances
tissue inhibitor of metalloproteinase-1 generation in fibro-
blasts [26]. Recently, IL-13 was selectively expressed in
the lungs using a Clara cell promoter [27]. The phenotype
of the transgenic mice expressing IL-13 demonstrated
airway epithelial cell hypertrophy, mucus cell metaplasia,
the hyper-production of neutral and acidic mucus, and
subepithelial airway fibrosis [27]. These data demonstrate
both the pro-fibrotic effects of IL-13 on collagen homeo-
stasis and the potential differential regulation of collagen
homeostasis in fibroblast subtypes by IL-13.
The similarities and overlapping functions of IL-4 and IL-13
have led to an interest in the IL-13 receptor (IL-13R)
complex and its relationship to the IL-4 receptor (IL-4R)
complex. The IL-4R complex is composed of at least two
subunits, IL-4Rα and the IL-2Rγ (common γ chain). The
IL-13 receptor complex is composed of various combina-
tions of IL-4Rα, IL-13Rα1, IL-13Rα2 and IL-2Rγ. IL-4Rα
appears to be an essential component of both the IL-4
and IL-13 receptors, although it can not by itself bind
IL-13. Studies of chronic Leishmaniasis using both IL-4–/–
mice and IL-4Rα–/– mice demonstrated that the IL-4–/–
mice were able to clear infection but the IL-4Rα–/– mice
developed progressive infection and died [28]. This indi-
cates an important and independent role for IL-13 recep-
tor signaling in this model. Similarly, in a schistosomiasis
model of hepatic fibrosis, reduction of hepatic fibrosis by
inhibition of IL-13, using soluble IL-13Rα2-Fc, was greater
than that in IL-4–/– mice.
Animal models of pulmonary fibrosis have provided insight
into the role of Th2 cytokines in the mediation of pul-
monary fibrosis, and recent studies have confirmed that
they are also involved in IPF. Lung tissue of patients with
IPF was examined to determine whether a Th1 or a Th2
pattern of cytokine expression was present [29]. Although
both Th1 (characterized by the expression of IFN-γ) and
Th2 (characterized by the expression of IL-4 and IL-5)
cytokines are expressed in IPF lung tissue, the expression
of Th2 cytokines predominated over that of IFN-γ [29].
This pattern of cytokine expression may be related to the
potential role of the humoral response in the pathogenesis
of IPF, or be related to the inability of IFN-γ to tilt the
balance away from an IL-4/IL-13-dependent pro-fibrotic
environment. The finding that IFN-γ levels are inversely
related to the levels of type III pro-collagen in the BALF of
IPF patients further supports the idea of an imbalance
between relatively high levels of Th2 cytokines and low
levels of IFN-γ [30]. The levels of IFN-γ correlated espe-
cially with patients that demonstrated progression of their
pulmonary fibrosis through further deterioration of their
pulmonary function [30]. These findings may be further
supported by the recent suggestion that treatment with
IFN-γ may be beneficial for IPF patients who fail to
respond to glucocorticoids [22]. These findings suggest
that the persistent imbalance in the expression of Th1 and
Th2 cytokines in the lung may be a mechanism by which
diffuse pulmonary fibrosis progresses.
IL-10 is a Th2 cytokine that inhibits a variety of innate and
adaptive immune activities. It inhibits a number of pro-
inflammatory cytokines, including IFN-γ, IL-1, TNF, IL-12,
and CXC and CC chemokines. While the exogenous
administration of IL-10 may protect the lung from injury in
response to either LPS or immune-complex deposition
[31], IL-10 can be detrimental to the host under conditions
of microorganism invasion [32]. The role of IL-10 in pul-
monary fibrosis is controversial. Interestingly, patients with
chronic hepatitis C who failed to respond to IFN have
shown improved histology and decreased liver fibrosis
when treated with IL-10 [33]. Paradoxically, patients that
are genetically predisposed to high levels of IL-10 produc-
tion, determined by genetic analysis of the IL-10 locus,
have a poor response to IFN-α [34]. Exogenous adminis-
tration of IL-10 using a liposomal vector significantly inhib-
ited bleomycin-induced pulmonary fibrosis in a murine
model [35]. IL-10 downregulates quartz-induced pul-
monary inflammation and cell activation in a rat model
[36]. In contrast, silica induces fibrosis in the NMRI strain
of mice that display decreased TNF activity and protracted
overproduction of IL-10 [37]. Similarly, IL-10–/– mice that
have been exposed to silica show increased inflammation
but decreased fibrosis, suggesting that IL-10 has both
anti-inflammatory and pro-fibrotic activities [38]. With the
mounting evidence that IPF involves a Th2-type profile, the
possibility of IL-10 exacerbating the disease cannot be
excluded.
Interestingly IL-9, a Th2 cytokine that has been implicated
in the pathogenesis of asthma, has been shown to attenu-
ate silica-induced pulmonary fibrosis in a murine model
[39]. This was demonstrated in both transgenic mice that
systemically over-expressed IL-9 and wild-type mice that
received systemic IL-9 [39]. Of particular interest is the
fact that the over-expression of IL-9 was paradoxically
associated with a reduced shift towards a Th2 response
[39]. One possible explanation for this may be that the
artificial over-expression of IL-9 invokes a different Th2
response than the normal expression of IL-9 [40].
Chemokines
Human CXC, CC, C and CX3C chemokines are four
closely related polypeptide families of potent chemotactic
factors for neutrophils, eosinophils, basophils, monocytes,
mast cells, dendritic cells, NK cells and T and B lympho-
Respiratory Research    Vol 3 No 1 Keane and Strieter
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groups according to whether or not their structure/func-
tion domain contains the three amino acid sequence Glu-
Leu-Arg (the ELR motif), which, when present, precedes
the first cysteine residue in the primary structure. The
ELR+ CXC chemokines are chemoattractants for neu-
trophils and act as potent angiogenic factors. In contrast,
the ELR– CXC chemokines are chemoattractants for
mononuclear leukocytes but are potent inhibitors of angio-
genesis. There is ~20–40% homology between the
members of the four chemokine families. Chemokines
have been found to be produced by an array of cells,
including monocytes, alveolar macrophages, neutrophils,
platelets, eosinophils, mast cells, T and B lymphocytes,
NK cells, keratinocytes, mesangial cells, epithelial cells,
hepatocytes, fibroblasts, smooth muscle cells, mesothelial
cells, and endothelial cells. These cells can produce
chemokines in response to a variety of factors that trigger
the innate immune response, including pattern recogni-
tion, ligands, IL-1, TNF, C5a, leukotriene B4 and IFNs.
The signals responsible for the recruitment of neutrophils
to the lung, and the perpetuation of the neutrophilic alve-
olitis of IPF, have not been fully characterized. Levels of
the CXC chemokine IL-8/CXCL8 are significantly elevated
in patients with IPF compared to either normal or patients
with sarcoidosis, which correlates with the presence of
neutrophils in the BALF [41,42]. In addition, these studies
have suggested that the levels of IL-8/CXCL8 in IPF may
correlate with poor prognosis [42]. These findings
suggest that factors that modulate the activity of IL-
8/CXCL8 could potentially influence the balance of inflam-
matory and anti-inflammatory mechanisms during the
pathogenesis of ILD.
Several studies have demonstrated the presence of CC
chemokines in human ILD [43]. Elevated levels of
macrophage inflammatory protein (MIP)-1α/CCL3 have
been associated with both sarcoidosis and IPF [43]. Fur-
thermore, pulmonary fibroblasts isolated from patients with
IPF produced greater amounts of MIP-1α/CCL3 after
challenge with IL-1β than similarly treated pulmonary
fibroblasts recovered from patients without fibrotic lung
disease. Similar to the findings for MIP-1α/CCL3,
macrophage chemotactic protein (MCP)-1/CCL2 has
been found to be significantly elevated in ILD [43].
MCP-1/CCL2 has been detected in pulmonary epithelial
cells, mononuclear phagocytes, fibroblasts, endothelial
cells and vascular smooth muscle cells [43]. In addition, in
the presence of either TNF or IL-1β, MCP-1/CCL2 pro-
duction from isolated pulmonary fibroblasts from patients
with IPF is greater than in the same cells from normal con-
trols [43], and pulmonary fibroblasts from patients with IPF
demonstrate a reduced ability to downregulate their
MCP-1/CCL2 expression in the presence of either
prostaglandin E2 or glucocorticoids [43]. These findings
suggest that both MIP-1α/CCL3 and MCP-1/CCL2 are
expressed in increased amounts within the airspace and
interstitium of patients with ILD, and that these
chemokines may be important mediators of mononuclear
cell recruitment that characterize and perpetuate pul-
monary fibrosis.
Furthermore, it has been shown that MCP-1/CCL2 can
stimulate IL-4 production and its over-expression is asso-
ciated with defects in cell-mediated immunity, indicating
that it might be involved in Th2 polarization [44].
MCP-1/CCL2-deficient mice are unable to mount Th2
responses. Lymph node cells from immunized
MCP-1/CCL2–/– mice synthesize extremely low levels of
IL-4, IL-5 and IL-10, but normal amounts of IFN-γ and IL-2
[44]. Thus, MCP-1/CCL2 may have both a direct role in
the pathogenesis of pulmonary fibrosis through its effects
on monocytes, and an indirect role through the control of
T helper cell polarization and the profile of cytokine pro-
duction. Similarly, the murine CC chemokine C10/CCL6
is differentially regulated by Th1 and Th2 cytokines [45].
Bone marrow derived macrophages produce C10/CCL6
in response to IL-4, IL-10 and IL-13 in a dose-dependent
manner [45]. In contrast, IFN-γ inhibits IL-3 and granulo-
cyte-macrophage colony-stimulating factor induced
expression of C10/CCL6 [45]. This is further evidence for
the interaction between CC chemokines and Th2
cytokines and suggests that chemokines may have an
important role in the switch towards a pro-fibrotic Th2-
type phenotype.
The importance of receptor polymorphisms in various
disease states has been demonstrated recently. CCR5 is
the major receptor for MIP-1α/CCL3, MIP-1β/CCL4 and
RANTES/CCL5. Homozygosity for the CCR5∆32 muta-
tion has been shown to predict for prolonged renal allo-
graft survival (90% at 20 years), reduced risk of asthma
and decreased severity of rheumatoid arthritis [46]. In con-
trast, there was an increased frequency of the CCR5∆32
allele in patients with sarcoidosis that was associated with
more apparent disease and an increased need for cortico-
steroids [47]. This suggests that CCR5∆32 is associated
with altered susceptibilty to immmunologically mediated
diseases and that the balance between chemokines and
their appropriately expressed receptors is necessary for
the full manifestation of various diseases.
CXC chemokines in the regulation of
angiogenesis and promotion of pulmonary
fibrosis
Angiogenesis is a fundamental component of inflammation
and wound repair. It has only recently become apparent,
however, that dysregulated angiogenesis may be impor-
tant in the support of fibroplasia and deposition of extra-
cellular matrix that occurs during chronic fibroproliferative
disorders such as IPF. The existence of neovascularization
Available online http://respiratory-research.com/content/3/1/5
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the lungs of patients with widespread interstitial fibrosis.
This idea has been further substantiated with evidence of
extensive neovascularization during the pathogenesis of
pulmonary fibrosis in a rat model of bleomycin-induced
pulmonary fibrosis [49].
Angiogenesis in pulmonary fibrosis is related to the over-
expression of ELR+ CXC chemokines relative to the
decreased expression of angiostatic (ELR–) interferon-
inducible CXC chemokines. Lung tissue from patients with
IPF has markedly increased angiogenic activity that is
almost entirely attributable to the imbalance caused by the
overexpression of the angiogenic ELR+ CXC chemokine
IL-8/CXCL8 and the relative downregulation of the angio-
static interferon-inducible CXC chemokine IP-10/CXCL10
[50]. To determine whether the imbalance in the expres-
sion of these CXC chemokines is relevant to the patho-
genesis of pulmonary fibrosis, the expression and
biological activity of murine MIP-2/CXCL2 (an angiogenic
ELR+ CXC chemokine) and the angiostatic CXC
chemokine IP-10/CXCL10 were correlated with the extent
of fibrosis during bleomycin-induced pulmonary fibrosis in
a murine model system [51,52]. Increased MIP-2/CXCL2
activity correlated with increased pulmonary fibrosis
whereas increased IP-10/CXCL10 activity correlated with
attenuated pulmonary fibrosis [51,52]. Moreover, both the
depletion of endogenous MIP-2/CXCL2 by passive immu-
nization with neutralizing antibodies and the administration
of exogenous IP-10/CXCL10 to the animals during
bleomycin exposure resulted in a marked attenuation of
pulmonary fibrosis that was entirely attributable to a reduc-
tion in angiogenesis in the lung [51,52]. These findings
support the notion that angiogenesis is a critical biological
event that supports fibroplasia and deposition of extracel-
lular matrix in the lung during pulmonary fibrosis. Further-
more, with the recent demonstration of the efficacy of
IFN-γ in the treatment of patients with IPF [22], these
studies support the idea that IFN-γ may mediate its effect,
in part, by shifting the imbalance in the expression of ELR+
and ELR– CXC chemokines to favor an angiostatic envi-
ronment, which would lead to inhibition of dysregulated
neovascularization/vascular remodeling, fibroproliferation
and deposition of extracellular matrix in IPF patients.
Conclusions
Inflammation in the lung involves a delicate balance
between pro-inflammatory and anti-inflammatory media-
tors, with the balance of cytokines dictating the ultimate
response to initial injury. The presence of natural inhibitors
of IL-1 and TNF has long been recognized. Increasing evi-
dence suggests that an imbalance in Th1 and Th2
cytokine profiles is important in diffuse lung disease and
the fibrotic response. There is now also evidence that
chemokines are involved in this polarization, supporting
the importance of cytokine networks in the pathogenesis
of diffuse lung disease. Similarly, the role of angiogenesis
is becoming increasingly recognized in chronic inflamma-
tion with evidence of imbalances in the mediators of
angiogenesis in a variety of chronic inflammatory disor-
ders. Therapeutic interventions directed towards alter-
ations in cytokine phenotypic profiles may prove beneficial
in the treatment of diffuse lung disease.
Acknowledgements
This work was supported, in part, by National Institutes of Health grants
P01 HL67665 (MPK and RMS), HL03906 (MPK) and CA 87879 and
HL60289 (RMS). MPK is the holder of a Dalsemer Scholar research
award from the American Lung Association.
References
1. Dinarello CA: Interleukin-1 beta, interleukin-18, and the inter-
leukin-1 beta converting enzyme. Ann NY Acad Sci 1998, 856:
1-11.
2. Murphy JE, Robert C, Kupper TS: Interleukin-1 and cutaneous
inflammation: a crucial link between innate and acquired
immunity. J Invest Dermatol 2000, 114:602-608.
3. Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: evo-
lutionarily conserved mediators of immune responses. Annu
Rev Immunol 1998, 16:225-260.
4. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J: Transient
expression of IL-1beta induces acute lung injury and chronic
repair leading to pulmonary fibrosis. J Clin Invest 2001, 107:
1529-1536.
5. Piguet P, Vesin C, Grau G, Thompson RC: Interleukin 1 recep-
tor anatgonist (IL-1ra) prevents or cures pulmonary fibrosis
elicited in mice by bleomycin or silica. Cytokine 1993, 5:57-61.
6. Rolfe MW, Standiford TJ, Kunkel SL, Burdick MD, Gilbert AR,
Moore SA, Lynch JP, Strieter RM: Interleukin-1 receptor antago-
nist expression in sarcoidosis. Am Rev Respir Dis 1993, 148:
1378-1384.
7. Smith DR, Kunkel SL, Standiford TJ, Rolfe MW, Lynch JP 3rd, Aren-
berg DA, Wilke CA, Burdick MD, Martinez FJ, Hampton JN, Whyte
RI, Orringer MB, Strieter RM: Increased interleukin-1 receptor
antagonist in idiopathic pulmonary fibrosis. A compartmental
analysis. Am J Respir Crit Care Med 1995, 151:1965-1973.
8. Bazzoni F, Beutler B: The tumor necrosis factor ligand and
receptor families. N Engl J Med 1996, 334:1717-1725.
9. Kuwano K, Hagimoto N, Kawasaki M, Yatomi T, Nakamura N,
Nagata S, Suda T, Kunitake R, Maeyama T, Miyazaki H, Hara N:
Essential roles of the Fas-Fas ligand pathway in the develop-
ment of pulmonary fibrosis. J Clin Invest 1999, 104:13-19.
10. Genersch E, Hayess K, Neuenfeld Y, Haller H: Sustained ERK
phosphorylation is necessary but not sufficient for MMP-9
regulation in endothelial cells: involvement of Ras-dependent
and -independent pathways. J Cell Sci 2000, 113:4319-4330.
11. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P: Tumor
necrosis factor/cachectin plays a key role in bleomycin-
induced pneumopathy. J Exp Med 1989, 170:655-663.
12. Piguet PF, Vesin C: Treatment by human recombinant soluble
TNF receptor of pulmonary fibrosis induced by bleomycin or
silca in mice. Eur Respir J 1994, 7:515-518.
13. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL,
Gauldie J: Transfer of tumor necrosis factor-alpha to rat lung
induces severe pulmonary inflammation and patchy intersti-
tial fibrogenesis with induction of transforming growth factor-
beta1 and myofibroblasts. Am J Pathol 1998, 153:825-832.
14. Romagnani S: Th1/Th2 cells. Inflamm Bowel Dis 1999, 5:285-
294.
15. Duncan MR, Berman B: Differential regulation of collagen, gly-
cosaminoglycan, fibronectin, and collagenase activity produc-
tion in cultured human adult dermal fibroblasts by
interleukin-1-alpha and beta and tumornecrosis factor-alpha
and beta. J Invest Dermatol 1989, 92:699-706.
16. Giri SN, Hyde DM, Marafino BJ: Ameliorating effect of murine
interferon gamma on bleomycin-induced lung collagen fibro-
sis in mice. Biochem Med Metab Biol 1986, 36:194-197.
17. Brody AR, Bonner JC, Badgett A: Recombinant interferon-
gamma reduces PDGF-induced lung fibroblast growth but
Respiratory Research    Vol 3 No 1 Keane and Strieter
Page 6 of 7
(page number not for citation purposes)stimulates PDGF production by alveolar macrophages in vitro.
Chest 1993, 103:121S-122S.
18. Lewis M, Amento EP, Unemori EN: Transcriptional inhibition of
stromelysin by interferon-gamma in normal human fibrob-
lasts is mediated by the AP-1 domain. J Cell Biochem 1999,
72:373-386.
19. Spoelstra FM, Postma DS, Hovenga H, Noordhoek JA, Kauffman
HF: Interferon-gamma and interleukin-4 differentially regulate
ICAM-1 and VCAM-1 expression on human lung fibroblasts.
Eur Respir J 1999, 14:759-766.
20. Keane MP, Belperio JA, Burdick MD, Strieter RM: IL-12 attenu-
ates bleomycin-induced pulmonary fibrosis. Am J Physiol
Lung Cell Mol Physiol 2001, 281:L92-97.
21. Hein R, Behr J, Hundgen M, Hunzelmann N, Meurer M, Braun-
Falco O, Urbanski A, Krieg T: Treatment of systemic sclerosis
with gamma-interferon. Br J Dermatol 1992, 126:496-501.
22. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH: A pre-
liminary study of long-term treatment with interferon gamma-
1b and low-dose prednisolone in patients with idiopathic
pulmonary fibrosis. N Engl J Med 1999, 341:1264-1269.
23. Postlethwaite AE, Holness MA, Katai H, Raghow R: Human fibrob-
lasts synthesize elevated levels of extracellular matrix proteins
in response to interleukin-4. J Clin Invest 1992, 90:1479-1485.
24. Rankin JA, Picarella DE, Geba GP, Temann UA, Prasad B,
DiCosmo B, Tarallo A, Stripp B, Whitsett J, Flavell RA: Pheno-
typic and physiologic characterization of transgenic mice
expressing interleukin 4 in the lung: lymphocytic and
eosinophilic inflammation without airway hyperreactivity. Proc
Natl Acad Sci USA 1996, 93:7821-7825.
25. Chensue SW, Warmington K, Ruth JH, Lukacs N, Kunkel SL:
Mycobacterial and schistosomal antigen-elicited granuloma
formation in IFN-gamma and IL-4 knockout mice: analysis of
local and regional cytokine and chemokine networks. J
Immunol 1997, 159:3565-3573 [published erratum appears in J
Immunol 1999, 162:3106].
26. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM,
Essayan DM: Interleukin-13 modulates collagen homeostasis
in human skin and keloid fibroblasts. J Pharmacol Exp Ther
2000, 292:988-994.
27. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y,
Elias JA: Pulmonary expression of interleukin-13 causes
inflammation, mucus hypersecretion, subepithelial fibrosis,
physiologic abnormalities, and eotaxin production. J Clin
Invest 1999, 103:779-788.
28. Mohrs M, Ledermann B, Kohler G, Dorfmuller A, Gessner A,
Brombacher F: Differences between IL-4- and IL-4 receptor
alpha-deficient mice in chronic leishmaniasis reveal a protec-
tive role for IL-13 receptor signaling. J Immunol 1999,  162:
7302-7308.
29. Wallace WAH, Ramage EA, Lamb D, Howie EM: A type 2 (Th2-
like) pattern of immune response predominates in the pul-
monary interstitium of patients with crytogenic fibrosing
alveolitis (CFA). Clin Exp Immunol 1995, 101:436-441.
30. Kuroki S, Ohta A, Sueoka N, Katoh O, Yamada H, Yamaguchi M:
Determination of various cytokines and type III procollagen
aminopeptide levels in bronchoalveolar lavage fluid of the
patients with pulmonary fibrosis: inverse correlation between
type III procollagen aminopeptide and interferon-γ γ in progres-
sive fibrosis. Brit J Rheum 1995, 34:31-36.
31. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL: Neutraliza-
tion of IL-10 increases lethality in endotoxemia. Cooperative
effects of macrophage inflammatory protein-2 and tumor
necrosis factor. J Immunol 1995, 155:2222-2229.
32. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman
RE, Standiford TJ: Neutralization of IL-10 increases survival in
a murine model of Klebsiella pneumonia. J Immunol 1995,
155:722-729.
33. Nelson DR, Lauwers GY, Lau JY, Davis GL: Interleukin 10 treat-
ment reduces fibrosis in patients with chronic hepatitis C: a
pilot trial of interferon nonresponders. Gastroenterology 2000,
118:655-660.
34. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse
C, Powell EE: Interleukin-10 promoter polymorphism predicts
initial response of chronic hepatitis C to interferon alfa. Hepa-
tology 1999, 30:526-530.
35. Arai T, Abe K, Matsuoka H, Yoshida M, Mori M, Goya S, Kida H,
Nishino K, Osaki T, Tachibana I, Kaneda Y, Hayashi S: Introduc-
tion of the interleukin-10 gene into mice inhibited bleomycin-
induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol
2000, 278:L914-922.
36. Driscoll KE, Carter JM, Howard BW, Hassenbein D, Burdick M,
Kunkel SL, Strieter RM: Interleukin-10 regulates quartz-
induced pulmonary inflammation in rats. Am J Physiol 1998,
275:L887-894.
37. Huaux F, Lardot C, Arras M, Delos M, Many MC, Coutelier JP,
Buchet JP, Renauld JC, Lison D: Lung fibrosis induced by silica
particles in NMRI mice is associated with an upregulation of
the p40 subunit of interleukin-12 and Th-2 manifestations. Am
J Respir Cell Mol Biol 1999, 20:561-572.
38. Huaux F, Louahed J, Hudspith B, Meredith C, Delos M, Renauld
JC, Lison D: Role of interleukin-10 in the lung response to
silica in mice. Am J Respir Cell Mol Biol 1998, 18:51-59.
39. Arras M, Huaux F, Vink A, Delos M, Coutelier JP, Many MC, Bar-
barin V, Renauld JC, Lison D: Interleukin-9 reduces lung fibro-
sis and type 2 immune polarization induced by silica particles
in a murine model. Am J Respir Cell Mol Biol 2001, 24:368-
375.
40. Hoyle GW, Brody AR: IL-9 and lung fibrosis: a Th2 good guy?
Am J Respir Cell Mol Biol 2001, 24:365-367.
41. Lynch I, J.P., Standiford TJ, Kunkel SL, Rolfe MW, Strieter RM:
Neutrophilic alveolitis in idiopathic pulmonary fibrosis: the
role of interleukin-8. Am Rev Respir Dis 1992, 145:1433-1438.
42. Southcott AM, Jones KP, Li D, Majumdar S, Cambrey AD, Pante-
lidis P, Black CM, Laurent GJ, Davis BH, Jeffrey PK, et al.: Inter-
leukin-8, differential expression in lone fibrosing alveolitis and
systemic sclerosis. Am J Respir Crit Care Med 1995,  151:
1604-1612.
43. Standiford TJ, Rolfe MW, Kunkel SL, Lynch JPI, Burdick MD,
Gilbert AR, Orringer MB, Whyte RI, Strieter RM: Macrophage
inflammatory protein-1α α expression in interstitial lung
disease. J Immunol 1993, 151:2852-2863.
44. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ: Control of
TH2 polarization by the chemokine monocyte chemoattrac-
tant protein-1. Nature 2000, 404:407-411.
45. Orlofsky A, Wu Y, Prystowsky MB: Divergent regulation of the
murine CC chemokine C10 by Th(1) and Th(2) cytokines.
Cytokine 2000, 12:220-228.
46. Fischereder M, Luckow B, Hocher B, Wuthrich RP, Rothenpieler
U, Schneeberger H, Panzer U, Stahl RA, Hauser IA, Budde K,
Neumayer H, Kramer BK, Land W, Schlondorff D: CC chemokine
receptor 5 and renal-transplant survival. Lancet  2001,  357:
1758-1761.
47. Petrek M, Drabek J, Kolek V, Zlamal J, Welsh KI, Bunce M, Weigl
E, Du Bois R: CC chemokine receptor gene polymorphisms in
Czech patients with pulmonary sarcoidosis. Am J Respir Crit
Care Med 2000, 162:1000-1003.
48. Turner-Warwick M: Precapillary systemic-pulmonary anasto-
moses. Thorax 1963, 18:225-237.
49. Peao MND, Aguas AP, DeSa CM, Grande NR: Neoformation of
blood vessels in association with rat lung fibrosis induced by
bleomycin. Anat Rec 1994, 238:57-67.
50. Keane MP, Arenberg DA, Lynch JP 3rd, Whyte RI, Iannettoni MD,
Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B,
Kunkel SL, Strieter RM: The CXC chemokines, IL-8 and IP-10,
regulate angiogenic activity in idiopathic pulmonary fibrosis. J
Immunol 1997, 159:1437-1443.
51. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA,
Smith RE, Burdick MD, Kunkel SL, Strieter RM: Neutralization of
the CXC chemokine, macrophage inflammatory protein-2,
attenuates bleomycin-induced pulmonary fibrosis. J Immunol
1999, 162:5511-5518.
52. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue
YY, Strieter RM: IFN-gamma-inducible protein-10 attenuates
bleomycin-induced pulmonary fibrosis via inhibition of angio-
genesis. J Immunol 1999, 163:5686-5692.
Available online http://respiratory-research.com/content/3/1/5
Page 7 of 7
(page number not for citation purposes)